Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Reset

18 trials match this view; 41 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 797 across 18 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

201933
202011
202144
202255
202311
202411
202533

Current indexed registry status

Completed1111
Unknown status33
Recruiting22
Active, not recruiting11
Terminated11

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

18 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study

NCT04959253

Treatment Resistant Depression
King's College London

PHASE2

Completed

Registry updated 2026-08-28

60

ACTUAL

2021-06-21
2024-12-18
2024-12-18
Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)

NCT05723276

Functional Neurological Disorder
King's College London

NA

Completed

Registry updated 2026-07-23

20

ACTUAL

2024-02-14
2026-04-14
2026-07-07
A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

NCT07050368

Healthy Volunteer
MycoMedica Life Sciences PBC

PHASE1

Completed

Registry updated 2026-02-13

20

ACTUAL

2025-07-28
2026-01-13
2026-01-13
Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study

NCT06798636

Self Harm
Imperial College London

EARLY_PHASE1

Recruiting

Registry updated 2025-12-05

30

ESTIMATED

2025-10-01
2026-08-31
2026-10-31
Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.

NCT06815653

Healthy
University College, London

PHASE1

Recruiting

Registry updated 2025-11-26

40

ESTIMATED

2025-03-01
2026-03
2026-12
Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.

NCT07164755

Depression - Major Depressive Disorder
King's College London

Phase not reported

Active, not recruiting

Registry updated 2025-09-10

46

ACTUAL

2021-06-21
2026-09
2026-09
Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)

NCT05651126

Autism Spectrum Disorder
King's College London

NA

Completed

Registry updated 2025-07-28

67

ACTUAL

2022-12-12
2024-08-23
2024-08-23
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT05312151

Post Traumatic Stress Disorder
COMPASS Pathways

PHASE2

Completed

Registry updated 2025-06-13

22

ACTUAL

2022-06-10
2024-02-12
2024-02-12
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

NCT05481736

Anorexia Nervosa
COMPASS Pathways

PHASE2

Completed

Registry updated 2024-12-04

32

ACTUAL

2022-10-12
2024-11-18
2024-11-18
PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)

NCT06258031

Obsessive-Compulsive Disorder
Imperial College London

PHASE1

Completed

Registry updated 2024-11-06

19

ACTUAL

2022-10-28
2024-06-28
2024-07-24
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

NCT03429075

Depressive Disorder, Major
Imperial College London

PHASE2

Completed

Registry updated 2024-10-24

59

ACTUAL

2019-01-07
2020-04-17
2020-10-17
Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study

NCT04505189

Anorexia Nervosa
Imperial College London

PHASE1, PHASE2

Completed

Registry updated 2024-06-17

21

ACTUAL

2021-05-28
2023-12-11
2024-06-12
Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action

NCT05548075

Fibromyalgia
Imperial College London

Phase not reported

Unknown status

Registry updated 2024-01-19

20

ESTIMATED

2022-08-15
2024-01-10
2024-07-30
Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans

NCT05876481

PTSD
Combat Stress

PHASE2

Unknown status

Registry updated 2023-05-25

8

ESTIMATED

2023-06
2025-07
2025-08
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT03775200

Treatment Resistant Depression
COMPASS Pathways

PHASE2

Completed

Registry updated 2023-04-24

233

ACTUAL

2019-03-01
2021-07-30
2021-09-27
An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

NCT04905121

Short Lasting Unilateral Neuralgiform Headache Attacks
Beckley Psytech Limited

PHASE1

Terminated

Registry updated 2022-10-12

4

ACTUAL

2021-08-11
2022-04-22
2022-04-22
Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)

NCT04519957

Treatment Resistant Depression
COMPASS Pathways

Phase not reported

Completed

Registry updated 2022-09-22

66

ACTUAL

2020-07-20
2022-08-11
2022-08-11
A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.

NCT03661125

Parkinson Disease Psychosis
King's College London

EARLY_PHASE1

Unknown status

Registry updated 2019-08-13

30

ESTIMATED

2019-04-11
2021-09-01
2021-09-01

Reported research facilities

Clinical Research Facility, King's College HospitalLondon, London, United Kingdom
South London and Maudsley NHS Foundation TrustLondon, United Kingdom
Hammersmith Medicines Research (HMR)London, United Kingdom
Imperial College LondonLondon, United Kingdom
University College LondonLondon, United Kingdom
King's College London Institute of Psychiatry, Psychology and NeuroscienceLondon, United Kingdom
King's College LondonLondon, United Kingdom
Sunstone TherapiesRockville, Maryland, United States
Icahn School of Medicine at Mount SinaiNew York, New York, United States
Kings College London, Institute of Psychiatry, Psychology and NeurologyLondon, United Kingdom
Altman Clinical and Translational Research InstituteSan Diego, California, United States
Sheppard Pratt Health SystemBaltimore, Maryland, United States
Dell Medical SchoolAustin, Texas, United States
Tallaght University HospitalDublin, Ireland
CIPPRes ClinicLondon, United Kingdom
Imperial College Hammersmith campusLondon, United Kingdom
Combat StressLeatherhead, Surrey, United Kingdom
Kadima Neuropsychiatry InstituteLa Jolla, California, United States
Altman Clinical and Translational Research Institute, University of CaliforniaSan Diego, California, United States
Stanford Department of PsychiatryStanford, California, United States
Mood and Anxiety Disorders Program Emory University School of MedicineAtlanta, Georgia, United States
Ray Worthy Psychiatry LLCNew Orleans, Louisiana, United States
New York State Psychiatric InstituteNew York, New York, United States
UT Center of Excellence on Mood Disorders, University of Texas Health Science CenterHouston, Texas, United States
Canadian Rapid Treatment Centre of ExcellenceMississauga, Ontario, Canada
Centre for Addiction and Mental HealthToronto, Ontario, Canada
National Institute of Mental Health Czech RepublicKlecany, Czechia
Enhed for Psykiatrisk Forskning, Psykiatrien i AalborgAalborg, Denmark
Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin FranklinBerlin, Germany
Groningen University Medical CentreGroningen, Netherlands
Leiden University Medical CentreLeiden, Netherlands
Utrecht University Medical CentreUtrecht, Netherlands
Unidade de Neuropsiquiatria, Centro Clinico ChampalimaudLisbon, Portugal
Hospital de Dia NumanciaBarcelona, Spain
Institute Hospital del Mar of Medical Research (IMIM)Barcelona, Spain
Clinical Research and Imaging CentreBristol, Avon, United Kingdom
Wolfson Research Centre, Campus for Ageing and VitalityNewcastle upon Tyne, Tyne and Wear, United Kingdom
St. Pancras Clinical ResearchLondon, United Kingdom
Greater Manchester Mental Health Foundation TrustManchester, United Kingdom
Sheaf House, Tallaght HospitalDublin, Ireland
Mitul MehtaLondon, Camberwell, United Kingdom

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.